rosuvastatin + omega-3

**Rosuvastatin + omega-3** is a combination therapy consisting of the HMG-CoA reductase inhibitor rosuvastatin and omega-3 fatty acids, primarily used in patients with dyslipidemia, residual hypertriglyceridemia, and/or cardiometabolic risk. Rosuvastatin lowers cholesterol levels by inhibiting HMG-CoA reductase, and omega-3 fatty acids (mainly EPA and DHA) reduce triglycerides and have anti-inflammatory and vascular protective effects. This combination is not an FDA-approved fixed-dose product but represents a regimen frequently studied for synergistic lipid-lowering and cardiovascular risk reduction. Combination therapy shows greater improvements in triglycerides, non-HDL cholesterol, endothelial function, and adiponectin levels compared to either agent alone, without increasing adverse events[1][2][3][4][5].

Other names

rosuvastatin and omega-3 fatty acidsrosuvastatin plus omega-3rosuvastatin/omega-3